University,
Museum,
Outline of health sciences,
Experience,
Sigma-Aldrich,
Eli Lilly,
North Carolina State University,
Student,
JIB,
Santa Clara University,
NIIMBL,
Thomas Jefferson University,
BTEC,
Merck,
University of Houston,
Growth,
Management NEWARK, Del., April 30, 2024 /PRNewswire/ -- The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce 63 students from 41 academic institutions have been selected to take part in the 2024 NIIMBL eXperience, the largest cohort since the Program's launch in 2019.
Key Points:
- NEWARK, Del., April 30, 2024 /PRNewswire/ -- The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce 63 students from 41 academic institutions have been selected to take part in the 2024 NIIMBL eXperience, the largest cohort since the Program's launch in 2019.
- The NIIMBL eXperience is a week-long, all-expenses-paid immersion program designed to introduce underrepresented groups including Black, Latinx, and Indigenous students completing their first or second year of college to career possibilities in the biopharmaceutical industry.
- "The NIIMBL eXperience has been a cornerstone of our efforts to expand and diversify talent pipelines for the biopharmaceutical industry," said John Balchunas, NIIMBL Workforce Director.
- Since 2019, the NIIMBL eXperience has served 80 students from 69 different academic institutions.
Retrieved on:
Wednesday, April 17, 2024
Over 120 representatives from 79 organizations representing industry, academia, non-profits, and government are expected to attend the two-day event focused on strengthening biopharma talent acquisition efforts.
Key Points:
- Over 120 representatives from 79 organizations representing industry, academia, non-profits, and government are expected to attend the two-day event focused on strengthening biopharma talent acquisition efforts.
- The event brings together talent acquisition personal, technical hiring managers, and community engagement leaders from industry with representatives from biopharma-centric universities, community colleges, non-profits, and career pathways intermediaries.
- "We hope that by bringing the entire talent ecosystem together, we can help the industry solve talent shortages more collaboratively and pre-competitively."
- The U.S. Biopharma Workforce Partnership Conference is part of NIIMBL's efforts to build national capacity to meet the talent acquisition, training, and workforce development needs of the biopharmaceutical manufacturing ecosystem.
Project,
University,
Sigma-Aldrich,
Pfizer,
University of California,
Agilent Technologies,
NIIMBL,
Workforce,
Government,
IPP,
Janssen Pharmaceuticals,
Organization,
Fine chemical The projects align with areas of need identified by NIIMBL and industry stakeholders.
Key Points:
- The projects align with areas of need identified by NIIMBL and industry stakeholders.
- "We are excited to expand our diverse project portfolio with these innovative new projects," said Chris Roberts, Associate Institute Director.
- Among the eight projects are two workforce development projects focused on data analytics training and strengthening the pipeline of neurodiverse talent.
- NIIMBL is composed of nearly 200 member organizations from academia, industry, government, and non-profit organization with a common goal to advance biopharmaceutical manufacturing.
Retrieved on:
Tuesday, October 17, 2023
Science,
ACPHS,
Hope,
Courage,
Student,
Lewis & Clark College,
Organization,
Engineering,
Experience,
North Carolina State University,
Geographic Locator Codes,
Ecosystem,
University,
Patient,
NIIMBL,
Nursing,
Tourism The NIIMBL eXperience program is an all-expenses paid biopharmaceutical manufacturing immersion program for university and community college students who have completed their first or second year of study.
Key Points:
- The NIIMBL eXperience program is an all-expenses paid biopharmaceutical manufacturing immersion program for university and community college students who have completed their first or second year of study.
- Specifically designed for Black, Latinx, and Indigenous students, the program strives to diversify the school-to-industry pipeline for the biopharmaceutical manufacturing industry.
- In August 2023, NIIMBL issued a Request for Applications seeking proposals from NIIMBL members to expand the eXperience program across the United States.
- Visit NIIMBL.org to learn more about the NIIMBL eXperience program and to apply for the 2024 cohort.
Retrieved on:
Tuesday, October 10, 2023
Vector (mathematics and physics),
Hope,
Government,
Viral vector,
University,
Doctor of Philosophy,
Ecosystem,
Workforce,
AAV,
NIIMBL,
Rare,
University of Massachusetts Chan Medical School,
Viral,
Patient,
Vaccine "There are thousands of rare diseases, many of which could be candidates for AAV-based gene therapy.
Key Points:
- "There are thousands of rare diseases, many of which could be candidates for AAV-based gene therapy.
- The initial structure of the Viral Vector Program will include:
Additionally, a key component of the Viral Vector Program includes a parallel initiative in workforce development for key capabilities in AAV vector manufacturing and analytics.
- NIIMBL will be hosting a webinar on the Viral Vector program on November 15, 2023.
- To register for the webinar and to learn more about NIIMBL and the Viral Vector program, visit NIIMBL.org/ViralVector .
Retrieved on:
Thursday, August 10, 2023
Viral vector,
NGS,
Request for information,
RFI,
VV,
AAV,
NIIMBL,
Massive parallel sequencing,
RFA,
Vaccine,
Risk management The objectives for this study are method development, sharing of best practices, and the establishment of a common protocol among the project teams.
Key Points:
- The objectives for this study are method development, sharing of best practices, and the establishment of a common protocol among the project teams.
- "As NIIMBL prepares for the launch of the Viral Vector (VV) Program, this study will be significant in developing a robust and reproducible NGS-based AAV characterization method for use within the Program.
- NIIMBL expects to release a Request for Application (RFA) based on capabilities assessments from the RFI2023.1 responses.
- For key dates, important information, and how to apply, go to the NGS Interlaboratory Study RFI page .
The PC7.1 Request for Proposals (RFP) and the 2024 NIIMBL eXperience Requests for Applications (RFA) are now open.
Key Points:
- The PC7.1 Request for Proposals (RFP) and the 2024 NIIMBL eXperience Requests for Applications (RFA) are now open.
- NIIMBL is currently accepting proposals through August 3, 2023, in response to PC 7.1 for key topic areas in technical and workforce development.
- Applicants will serve as a regional lead organization that will plan program logistics, recruit students, and run a NIIMBL eXperience Program in their respective region.
- "It is exciting to offer multiple funding opportunities to our members that span a range of interests and expertise," says Chris Roberts, Associate Institute Director, NIIMBL.
Lewis & Clark College,
Workforce,
Albany College of Pharmacy and Health Sciences,
Student,
Biopharma LLC,
Organization,
The First-Year Experience Program,
Patient,
Raritan Valley Community College,
NIIMBL,
Growth,
Ecosystem,
ACPHS,
Experience,
Nursing NEWARK, Del., April 25, 2023 /PRNewswire/ -- The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) has announced the selection of 44 college freshman and sophomores to participate in the 2023 NIIMBL eXperience Program, the largest cohort to date since the program launched in 2019.
Key Points:
- NEWARK, Del., April 25, 2023 /PRNewswire/ -- The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) has announced the selection of 44 college freshman and sophomores to participate in the 2023 NIIMBL eXperience Program, the largest cohort to date since the program launched in 2019.
- "We are thrilled at the response and growth of the NIIMBL eXperience Program this year," says John Balchunas, director of workforce development for NIIMBL.
- In November 2022, NIIMBL awarded over $200k to the three host sites through a request for application process earlier that year.
- Starting in June, the first of the three cohorts will begin and host students for a weeklong expense paid biopharmaceutical immersion program.
Biopharmaceutical,
Workforce,
Oregon Center for Advanced Technology Education,
NSF,
ATE,
Biotechnology,
National Science Foundation,
Innovation,
NIIMBL,
Part Two,
Ecosystem,
Fine chemical NEWARK, Del., March 28, 2023 /PRNewswire/ -- The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) issues Part II of a whitepaper series titled Innovation of the Biopharmaceutical Manufacturing Talent Pipeline, a series focused on highlighting non-traditional and novel solutions for the talent pipeline gap in the biopharmaceutical industry.
Key Points:
- NEWARK, Del., March 28, 2023 /PRNewswire/ -- The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) issues Part II of a whitepaper series titled Innovation of the Biopharmaceutical Manufacturing Talent Pipeline, a series focused on highlighting non-traditional and novel solutions for the talent pipeline gap in the biopharmaceutical industry.
- The newest whitepaper focuses on successes and challenges faced by community college biotechnology degree programs and makes the case for stronger engagement between industry and community colleges.
- It's our hope that by exposing more of these solutions to industry, we can drive some step change progress as talent funnels broaden and hiring risk tolerance increases in our industry," states John Balchunas, NIIMBL workforce director.
- This white paper is Part II of a larger series in which NIIMBL seeks to advance novel and non-traditional pathways that could strengthen talent pipelines for the biopharmaceutical manufacturing industry.
Retrieved on:
Tuesday, February 28, 2023
These projects were selected to best align with key focus areas identified by NIIMBL and the Bill and Melinda Gates Foundation (BMGF) to address industry needs.
Key Points:
- These projects were selected to best align with key focus areas identified by NIIMBL and the Bill and Melinda Gates Foundation (BMGF) to address industry needs.
- The Global Health Fund was established by NIIMBL with funding contributed by BMGF to develop and implement innovative technologies for vaccine and biological manufacturing that will accelerate development timelines and lower the cost of manufacturing, all in furtherance of BMGF's charitable objectives.
- "The recent pandemic highlighted several needs for vaccine development and manufacturing across multiple potential vaccine targets.
- NIIMBL has awarded approximately 142 technical, workforce development, and Global Health Fund projects through the Project Call process with a total project investment of over $111M since 2017 when the Institute launched.
